Verona

Verona Pharma successfully developed the inhaled dual phosphodiesterase PDE3/PDE4 inhibitor ensifentrine (Ohtuvayre®), which in 2024 became the first novel maintenance therapy for chronic obstructive pulmonary disease to win FDA approval in 20 years. Verona Pharma was a VIPE (Venture Investment in Public Equity), listed initially on the London AIM and subsequently on the Nasdaq with ticker symbol VRNA. The company was acquired by Merck for $10 billion.